United States HRES 242: Affirming the importance of the Orphan Drug Act, celebrating the over 750 new orphan therapies approved since its creation, and recognizing the need to continue supporting research and development for rare diseases.

Status: Referred to the Subcommittee on Health. (as of 2019-03-19)

State: United States · Session: 116 · Bill: HRES 242

Subjects: Congressional tributes, Drug safety, medical device, and laboratory regulation, Drug therapy, Health care costs and insurance, Health care coverage and access, Health care quality, Health promotion and preventive care, Medical research, Prescription drugs, Research and development

Sponsors: G. K. Butterfield, Bill Flores, Gus M. Bilirakis, Joe Neguse, John A. Yarmuth, SANFORD D. BISHOP, Susie Lee

View United States HRES 242 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.